TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35113805

Group type: EXPERIMENTAL
Intervention: AZD4017 (400 mg oral, bi-daily for 35 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33152538

Group type: EXPERIMENTAL
Intervention: Concurrent systemic antibiotics at catheter insertion
Number of subjects: 10269

Group type: COMPARATOR
Intervention: No antibiotics at catheter insertion
Number of subjects: 10269
Study: 32021141

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non‐EECP
Number of subjects: 72
Study: 36105248

Group type: EXPERIMENTAL
Intervention: Antithrombotic elastic socks combined with pneumatic treatment intervention
Number of subjects: 60
Study: 32300579

Group type: EXPERIMENTAL
Intervention: Intravenous ACBMNC infusion (5 × 10^7 cells/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study: 33769445

Group type: COMPARATOR
Intervention: No comedonecrosis (n = 76)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Comedonecrosis present
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Larger calcification span
Number of subjects: 129
Study: 33220488

Group type: EXPERIMENTAL
Intervention: Basic Implementation (BI; a large group didactic learning collaboratives)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Enhanced Implementation (EI; participatory small group learning collaboratives; enhanced consultation for site champions)
Number of subjects: 186
Study: 32500201

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 37
Study: 34077911

Group type: EXPERIMENTAL
Intervention: Informational intervention (monthly newsletters about park-based PA opportunities, park program brochures, trail maps, and activity guides)
Number of subjects: 171

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 171
Study: 36530477

Group type: EXPERIMENTAL
Intervention: Trigeminal ganglion block (2% lidocaine 0.5 mL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline (control group, C group, n=41)
Number of subjects: 82
Study: 32730948

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 29
Study: 35499362

Group type: EXPERIMENTAL
Intervention: Topical application of Epilobium fleischeri extract (twice daily for 4 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 23
Study: 32758405

Group type: COMPARATOR
Intervention: Community sample (unaffected by epilepsy)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Community sample (suspected epilepsy, did not seek care)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Hospital-based sample (PWE and caregivers)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Higher educational attainment and income
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Age, education, income, area of residence, presence of seizure symptoms
Number of subjects: 626

Group type: COMPARATOR
Intervention: Community participants screening negative for seizures
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Endorsement of treatment methods
Number of subjects: 626
Study: 35996845

Group type: EXPERIMENTAL
Intervention: Exercise group (n=12) participated in a 10-week supervised progressive walking program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n=12) maintained regular habits
Number of subjects: 24
Study: 33957621

Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triamterene 50 mg twice daily
Number of subjects: 12
Study: 32245480

Group type: EXPERIMENTAL
Intervention: CHM plus Liu Zi Jue (LZJ) exercises
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: CHM plus rehabilitation education
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo plus rehabilitation education
Number of subjects: 354
Study: 35187621

Group type: EXPERIMENTAL
Intervention: High-dose ghrelin (0.5 µg/kg/h)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Low-dose ghrelin (0.25 µg/kg/h)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ghrelin (both doses)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 33485734

Group type: EXPERIMENTAL
Intervention: Fitness Age
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Heart Age
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Percentage risk
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High risk results
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low risk results
Number of subjects: 180
Study: 32153120

Group type: EXPERIMENTAL
Intervention: Dietary protein pattern 2 (rich in fish and poultry)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Dietary protein patterns 1 and 3
Number of subjects: 788
Study: 36478501

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg/day, escalated to a maximum of 400 mg/day)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Tramadol (open-label period)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo (double-blind period)
Number of subjects: 252
Study: 34620310

Group type: EXPERIMENTAL
Intervention: Simplified Diabetes Nutrition Education (SDNE) for 12 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study: 32473654

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (ES) in the luteal phase prior to embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 37084125

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (80–110 mg/dL)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Moderate glycemic control (110–140 mg/dL)
Number of subjects: 128
Study: 32735809

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) wipe
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) cap
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% IPA wipe
Number of subjects: 180
Study: 32769657

Group type: EXPERIMENTAL
Intervention: Mayo Scissor technique
Number of subjects: 318

Group type: COMPARATOR
Intervention: Babcock clamp technique
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 318
Study: 35960115

Group type: EXPERIMENTAL
Intervention: Combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kangfuxin liquid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ultrasonic debridement and CPCF
Number of subjects: 0
Study: 33827990

Group type: EXPERIMENTAL
Intervention: AD-203 (rebamipide 150 mg) twice daily for 2 weeks
Number of subjects: 475

Group type: COMPARATOR
Intervention: Mucosta (rebamipide 100 mg) thrice daily for 2 weeks
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: AD-203 (rebamipide 150 mg)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Mucosta (rebamipide 100 mg)
Number of subjects: 475
Study: 34609547

Group type: EXPERIMENTAL
Intervention: Plasmalyte‐148 (PL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (SC)
Number of subjects: 90
Study: 35395741

Group type: EXPERIMENTAL
Intervention: Modified antenatal care (MAC) program with 4 in-person visits and 2 virtual meetings
Number of subjects: 8200

Group type: COMPARATOR
Intervention: Standard antenatal care (SAC) program with 8 in-person visits
Number of subjects: 8200
Study: 33059669

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed nets (LLINs) ownership
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: LLINs utilization
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: LLIN ownership
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: LLIN utilization conditional to presence of at least one net
Number of subjects: 2261
Study: 36271898

Group type: EXPERIMENTAL
Intervention: $10 financial incentive
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: $20 financial incentive
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: $40 financial incentive
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Mailed letters
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Automated calls
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Comparison group (no financial incentive)
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Time since enrollment (3 months)
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: Time since enrollment (12 months)
Number of subjects: 5200
Study: 32651644

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) + Codeine (30 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (Acetaminophen and Acetaminophen + Codeine)
Number of subjects: 39
Study: 32186286

Group type: COMPARATOR
Intervention: Regular Platform (RP) implants
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) implants
Number of subjects: 18
Study: 34853186

Group type: EXPERIMENTAL
Intervention: Ankle joint cooling
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Knee joint cooling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (seated without cooling)
Number of subjects: 20
Study: 32658610

Group type: EXPERIMENTAL
Intervention: udenafil treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 2
Study: 34792094

Group type: EXPERIMENTAL
Intervention: Zinc-biofortified rice (BFR)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control rice (CR)
Number of subjects: 520
Study: 33179377

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 3.4 mg/kg
Number of subjects: 196
Study: 35886341

Group type: EXPERIMENTAL
Intervention: Iontophoresis with Perskindol gel from the positive pole ("+" iontophoresis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iontophoresis with Perskindol gel from the negative pole ("-" iontophoresis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anodic galvanic treatment
Number of subjects: 100
Study: 33651976

Group type: EXPERIMENTAL
Intervention: Adherence to CONSORT guidelines
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CONSORT items adherence
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Underreported CONSORT items
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Journals' recommendations
Number of subjects: 80
Study: 32443285

Group type: EXPERIMENTAL
Intervention: Surgical treatment and prolonged antimicrobial therapy (median duration of antibiotics was 12 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 37
Study: 35490396

Group type: EXPERIMENTAL
Intervention: Withdraw from ASMs
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Continue ASMs
Number of subjects: 1004
Study: 35329209

Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (0.1%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cold water mouth rinse (WAT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLA)
Number of subjects: 11
Study: 36003294

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) - four cycles of 5 min blood pressure cuff inflation at 200 mmHg followed by 5 min reperfusion on the unaffected thigh.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group - only undergoes blood pressure measurements before and after the intervention period.
Number of subjects: 400
Study: 32651051

Group type: EXPERIMENTAL
Intervention: 600 mA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 700 mA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 mA
Number of subjects: 0
Study: 34946280

Group type: EXPERIMENTAL
Intervention: Dentapen R syringe
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 178
Study: 33028550

Group type: EXPERIMENTAL
Intervention: Active treatment (single‐pulse TMS to primary motor cortex (M1) above resting motor threshold)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inactive treatment (single‐pulse TMS to M1 below resting motor threshold)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 36006521

Group type: EXPERIMENTAL
Intervention: Safe Cholecystectomy modules
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usually scheduled CME activities (control group)
Number of subjects: 41
Study: 32242288

Group type: EXPERIMENTAL
Intervention: Dating Matters comprehensive TDV prevention model
Number of subjects: 3301

Group type: COMPARATOR
Intervention: Standard-of-care TDV prevention program
Number of subjects: 3301
Study: 32779534

Group type: EXPERIMENTAL
Intervention: Body-weight resistance exercise (BWR)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 23
Study: 32761909

Group type: EXPERIMENTAL
Intervention: Topical phenytoin (10% phenytoin USP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (carrier alone)
Number of subjects: 20
Study: 36224325

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg twice a day) in group A (S+)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg twice a day) in group C (S-)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo in group B (S+)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo in group D (S-)
Number of subjects: 158
Study: 35816305

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to hypoxemia
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to anemia
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to tachyarrhythmia
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to coronary mechanisms
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Type 1 myocardial infarction
Number of subjects: 1115
Study: 34387432

Group type: EXPERIMENTAL
Intervention: Autologous costal cartilage‐based open rhinoplasty
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Revision operation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 30
Study: 32770957

Group type: EXPERIMENTAL
Intervention: End-stage renal disease patients receiving CABG
Number of subjects: 48
Study: 35751944

Group type: EXPERIMENTAL
Intervention: Enhanced Training for counselors
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Report (PFR)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Basic Training for counselors
Number of subjects: 476

Group type: COMPARATOR
Intervention: No Feedback
Number of subjects: 476
Study: 33421315

Group type: EXPERIMENTAL
Intervention: Family empowerment program (8 weeks of group training sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care education (control group)
Number of subjects: 82
Study: 34461803

Group type: EXPERIMENTAL
Intervention: Urinary peptidomic profiling (UPP) communicated early during follow-up
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Home blood pressure telemonitoring (HTM) alone
Number of subjects: 1148
Study: 34167763

Group type: EXPERIMENTAL
Intervention: Peek Community Eye Health (Peek CEH) system
Number of subjects: 68348

Group type: COMPARATOR
Intervention: Standard care via periodic health centre‐based outreach clinics
Number of subjects: 68348
Study: 32572864

Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score
Number of subjects: 15968

Group type: EXPERIMENTAL
Intervention: CRUSADE score
Number of subjects: 15968

Group type: EXPERIMENTAL
Intervention: ACUITY score
Number of subjects: 15968
Study: 35630063

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia and purpurea supplementation plus vaginal hyaluronic acid for 3 months
Number of subjects: 153

Group type: COMPARATOR
Intervention: Echinacea angustifolia and purpurea supplementation alone for 3 months
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vaginal hyaluronic acid alone for 3 months
Number of subjects: 153
Study: 33814366

Group type: EXPERIMENTAL
Intervention: Non-medical students
Number of subjects: 465

Group type: COMPARATOR
Intervention: Medical students
Number of subjects: 465
Study: 35648286

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Second dose of immunoglobulin
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Eculizumab (monoclonal antibody against C5)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: ANX005 (humanized recombinant antibody against C1q)
Number of subjects: 100000
Study: 34158000

Group type: EXPERIMENTAL
Intervention: Group exercise intervention (12-week, moderate to vigorous aerobic exercise)
Number of subjects: 38
Study: 34304738

Group type: EXPERIMENTAL
Intervention: Hospital- and community-based intervention adapted from the Critical Time Intervention, including a six-month period of support in the community after hospital discharge.
Number of subjects: 0
Study: 32649617

Group type: EXPERIMENTAL
Intervention: Prophylactic implantation of a biological intraperitoneal mesh using Strattice (mesh group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard abdominal closure using a single, continuous running suture (no-mesh group)
Number of subjects: 48
Study: 35023547

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 33503656

Group type: EXPERIMENTAL
Intervention: Bedside washing of allogeneic erythrocyte units
Number of subjects: 75
Study: 34045378

Group type: EXPERIMENTAL
Intervention: Start antiplatelet therapy
Number of subjects: 537

Group type: COMPARATOR
Intervention: Avoid antiplatelet therapy
Number of subjects: 537
Study: 33716269

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Sedentary behavior (SB)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Light-intensity physical activity (LPA)
Number of subjects: 485
Study: 32996352

Group type: EXPERIMENTAL
Intervention: Schema-enhanced parent behavior therapy (SPBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Parent behavioral training (control group)
Number of subjects: 54
Study: 36433863

Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 118

Group type: COMPARATOR
Intervention: SCTG
Number of subjects: 118
Study: 34214098

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 290

Group type: COMPARATOR
Intervention: Opioid
Number of subjects: 290
Study: 36000769

Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care (TCC) program
Number of subjects: 722

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 722
Study: 33477587

Group type: EXPERIMENTAL
Intervention: FB group (nasal inspiratory restriction device with respiratory muscle training)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (without respiratory muscle training)
Number of subjects: 18
Study: 32559123

Group type: EXPERIMENTAL
Intervention: Science textbook chapter with added prosocial utility value
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (two unspecified control conditions)
Number of subjects: 0
Study: 32844674

Group type: EXPERIMENTAL
Intervention: Virtual Scribe Services (VSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional postencounter dictation (TD)
Number of subjects: 50
Study: 35606227

Group type: EXPERIMENTAL
Intervention: Atkins diet (55% fat, 25% protein, 20% carbohydrates)
Number of subjects: 24
Study: 33447966

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 60
Study: 35120541

Group type: EXPERIMENTAL
Intervention: Practice change intervention (multi-strategy including educational meetings and educational materials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice change intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33369329

Group type: EXPERIMENTAL
Intervention: Regular training of core muscle strength guided by ERAS concept
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional training method
Number of subjects: 94
Study: 34928302

Group type: EXPERIMENTAL
Intervention: mRNA vaccine (BNT162b2 or mRNA‐1273)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vector vaccine (Ad26COVS1)
Number of subjects: 201

Group type: COMPARATOR
Intervention: mRNA vaccine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Both mRNA and vector vaccines
Number of subjects: 201

Group type: COMPARATOR
Intervention: Vector vaccine
Number of subjects: 201
Study: 33202263

Group type: EXPERIMENTAL
Intervention: Active ABM training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham ABM training
Number of subjects: 40
Study: 34465677

Group type: EXPERIMENTAL
Intervention: Neurodynamics Nerve Flossing Technique (NFT) combined with conventional therapy program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy program
Number of subjects: 30
Study: 33210773

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by primary care nurses including motivational interview and individualized prescription of physical activity (150 min/week)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by primary care nurses
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 263
Study: 32613370

Group type: EXPERIMENTAL
Intervention: Prospective surveillance and early intervention model of care (PSM)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Education to health professionals and patients
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Adherence to nonoptional study appointments
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Sustained implementation of PSM
Number of subjects: 219
Study: 35343881

Group type: EXPERIMENTAL
Intervention: 1 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 g and 1 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45